UCL experts shared insights on advanced therapies

Last November, our TRO Head of Translational Research Group Dr Pamela Tranter joined other UCL experts at the Advanced Therapies Symposium held by UCL Queen Square Institute of Neurology, to reflect on the high-quality research and discoveries that permeate all of Queen Square and UCL and pave the way for therapeutic advances.

In the presentation, Dr Pamela Tranter shared that the grant writing success rate with the TRO involvement is close to 40% vs a national average of 6% to 25%, depending on the scheme. What's more, the Business and Innovation Group (B&IG) of TRO, which consists of a team of dedicated and experienced business and innovation managers, is positioned to foster collaborations between industry and academia.  

Click here to read the summary of insights shared by all speakers at the event.